Interestingly, treatment with the tyrosine kinase inhibitor STI571/Imatinib (Glivec) reduced CRC cell growth, MMP-2 activation, and MT1-MMP expression in another study [35]; accordingly, we have previously shown that Imatinib significantly reduces tumor cell adhesion, ECM degradation, and invasion by CRC cells through inhibition of Abi1 phosphorylation, a key regulator of cytoskeletal dynamics during cell migration [25]. This evidence concerns the gene MMP14 and colorectal carcinoma.